You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for 680C91
680C91 is a potent and selective inhibitor of tryptophan 2,3-dioxygenase (TDO) (Ki = 51 nM). Exhibits no activity against indoleamine 2,3-dioxygenase, monoamine oxidase A and B, 5-HT uptake or 5-HT1A, 1D, 2A and 2C receptors. Produces large increases in brain tryptophan and serotonin in vitro and in vivo in the rat.
Technical Data for 680C91
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for 680C91
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for 680C91
The following data is based on the product molecular weight 238.26. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||4.2 mL||20.99 mL||41.97 mL|
|5 mM||0.84 mL||4.2 mL||8.39 mL|
|10 mM||0.42 mL||2.1 mL||4.2 mL|
|50 mM||0.08 mL||0.42 mL||0.84 mL|
References for 680C91
References are publications that support the biological activity of the product.
Salter et al (1995) The effects of a novel and selective inhibitor of tryptophan 2,3-dioxygenase on tryptophan and serotonin metabolism in the rat. Biochem.Pharmacol. 17 1435 PMID: 7539265
Salter et al (1995) The effects of an inhibitor of tryptophan 2,3-dioxygenase and a combined inhibitor of tryptophan 2,3-dioxygenase and 5-HT reuptake in the rat. Neuropharmacology 34 217 PMID: 7617147
Opitz et al (2011) An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 478 197 PMID: 21976023
If you know of a relevant reference for 680C91, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: 680C91, 680C91 supplier, tryptophan, 2,3-dioxygenase, inhibits, TDO, inhibitors, catabolism, immune, checkpoints, Tryptophan, 2,3, dioxygenase, Immune, Checkpoints, 4392, Tocris Bioscience
3 Citations for 680C91
Citations are publications that use Tocris products. Selected citations for 680C91 include:
Breda et al (2016) Tryptophan-2,3-dioxygenase (TDO) inhibition ameliorates neurodegeneration by modulation of kynurenine pathway metabolites. Proc.Natl.Acad.Sci.U.S.A. 113 5435 PMID: 27114543
Bostian et al (2016) Kynurenine Signaling Increases DNA Polymerase Kappa Expression and Promotes Genomic Instability in Glioblastoma Cells. Chem Res Toxicol 29 101 PMID: 26651356
D'Amato et al (2015) A TDO2-AhR Signaling Axis Facilitates Anoikis Resistance and Metastasis in Triple-Negative Breast Cancer. Cancer Res 75 4651 PMID: 26363006
Do you know of a great paper that uses 680C91 from Tocris? Please let us know.
Reviews for 680C91
There are currently no reviews for this product. Be the first to review 680C91 and earn rewards!
Have you used 680C91?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Cancer Metabolism Poster
Adapted from the 2015 Cancer Product Guide, Edition 3, this poster summarizes the main targets for cancer metabolism researchers. Genetic changes and epigenetic modifications in cancer cells alter the regulation of cellular metabolic pathways. These distinct metabolic circuits could provide viable cancer therapeutic targets.